Adaptimmune Therapeutics Plc ADR’s recently made public that its Chief Commercial Officer Piccina Cintia unloaded Company’s shares for reported $22814.0 on Jun 18 ’24. In the deal valued at $0.93 per share,24,531 shares were sold. As a result of this transaction, Piccina Cintia now holds 38,293 shares worth roughly $33697.840000000004.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Rawcliffe Adrian sold 30,080 shares, generating $20,244 in total proceeds. Upon selling the shares at $0.67, the Chief Executive Officer now owns 44,848 shares.
Before that, Rawcliffe Adrian sold 9,304 shares. Adaptimmune Therapeutics Plc ADR shares valued at $7,350 were divested by the Chief Executive Officer at a price of $0.79 per share. As a result of the transaction, Rawcliffe Adrian now holds 14,104 shares, worth roughly $12411.52.
H.C. Wainwright initiated its Adaptimmune Therapeutics Plc ADR [ADAP] rating to a Buy in a research note published on July 30, 2024; the price target was $4. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in late May with a ‘”a Sector outperform”‘ rating. Bryan Garnier began covering ADAP with “Buy” recommendation on March 24, 2023. Guggenheim revised its rating on January 03, 2023. It rated ADAP as “a Buy” which previously was an “a Neutral”.
Price Performance Review of ADAP
On Tuesday, Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP] saw its stock jump 0.10% to $0.88. Over the last five days, the stock has lost -3.17%. Adaptimmune Therapeutics Plc ADR shares have risen nearly 10.97% since the year began. Nevertheless, the stocks have risen 34.15% over the past one year. While a 52-week high of $2.05 was reached on 03/08/24, a 52-week low of $0.42 was recorded on 01/17/24. SMA at 50 days reached $1.0434, while 200 days put it at $1.1302.
Levels Of Support And Resistance For ADAP Stock
The 24-hour chart illustrates a support level at 0.8668, which if violated will result in even more drops to 0.8536. On the upside, there is a resistance level at 0.8964. A further resistance level may holdings at 0.9128. The Relative Strength Index (RSI) on the 14-day chart is 37.59, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0320, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 72.22%. Stochastics %K at 20.93% indicates the stock is a holding.
How much short interest is there in Adaptimmune Therapeutics Plc ADR?
A steep rise in short interest was recorded in Adaptimmune Therapeutics Plc ADR stocks on 2024-09-30, dropping by -0.74 million shares to a total of 6.09 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-30 was 6.83 million shares. There was a decline of -12.13%, which implies that there is a negative sentiment for the stock.
